SPRY
ARS Pharmaceuticals, Inc
4.10$
-1.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | +313.6% | +4,086.7% | -90.8% | +97.1% | +106.8% | -13.6% | -19.2% | +48.4% | – | |
| – | +13.4% | +53.8% | +31.8% | -98.4% | +3,375.0% | +4.0% | +23.2% | +64.3% | -60.9% | +96.3% | +104.4% | – | |
| – | – | – | – | – | +4,127.5% | -95.3% | +173.3% | +126.5% | +2.4% | -34.1% | +26.9% | – | |
| – | +13.4% | +53.8% | +31.8% | -35.9% | -31.6% | -2.5% | +36.7% | -31.8% | +25.2% | +25.9% | +8.3% | – | |
| – | -54.4% | +16.7% | +12.4% | +115.6% | +87.7% | +13.6% | +32.1% | +37.6% | -19.8% | +20.4% | +7.4% | – | |
| – | -54.4% | +16.7% | +12.4% | +165.0% | +49.7% | +15.8% | +41.9% | +32.8% | -14.4% | +15.4% | +7.5% | – | |
| – | – | – | – | – | – | -178.8% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -6.1% | +1.6% | – | |
| – | – | – | – | – | – | -167.6% | – | – | – | – | – | – | |
| – | – | -100.8% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -168.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | -167.0% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.